The rate at which the heart deteriorates after Doxo treatment has finished without using any cardioprotective drugs would be well known from other studies. Why do you say it's impossible to know that?
Dr T implies that that rate is higher than the observed decline when using bisantrene in the historical study.
The rate at which the market awards upvotes and GAs makes as much sense as the market's under-valuation or over-valuation of biotech companies.
Ann: Breakthrough Zantrene Heart Protection Discovery, page-320
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.66 |
Change
-0.035(2.07%) |
Mkt cap ! $282.0M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.65 | $122.2K | 73.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 16785 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 2384 | 2 |
View Market Depth
| Last trade - 13.38pm 03/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |